114 results about "Muscle disease" patented technology

The invention relates to an antisense oligonucleotide targeted to the coding region of the human acetylcholinesterase (AChE), which selectively suppresses the AChE-R isoform of the enzyme. The antisense oligonucleotide is intended for use in the treatment and / or prevention of neuromuscular disorders, preferably myasthenia gravis. In addition, it can penetrate the blood-brain barrier (BBB) and destroy AChE-R within central nervous system neurons, while also serving as a carrier to transport molecules across the BBB.

The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185erbB2 receptor. These compounds are found to cause increased differentiation and survival of cardiac, skeletal and smooth muscle.

The invention relates to methods and materials for enhancing muscle mass or for the treatment of muscle disease in a subject, comprising introducing a cell which has a lower than normal level of myostatin signalling, into the subject.

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits activity of a disease allele associated with muscle disease. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

Electrical impedance myography (EIM) can be used for assessment and diagnosis of muscular disorders. EIM includes applying an electrical signal to a region of tissue and measuring a resulting signal. A characteristic of the region of tissue is determined based on the measurement. Performing EIM at different frequencies and modeling one or more impedance metrics as a function of frequency may provide impedance model parameters that can aid in the assessment and diagnosis. Devices are described that facilitate assessment and diagnosis using EIM.

Vegetarian amino acid sources are combined to create a protein blend that closely matches human muscle tissue in terms of amino acid composition. “Closely matching” means that the amino acid composition of the protein blend is within five percent (5%) of the amino acid composition of human muscle for all of the amino acids of the human muscle. The protein blend can be used as food or food supplement to facilitate and bolster muscle anabolism for healthy humans desiring such result and also to treat and or ameliorate the effects of certain diseases and conditions such as sarcopenia, cancer cachexia, HIV wasting, malnutrition, primary muscle diseases (myopathy) and side effects of corticosteroid therapy.

Acute and chronic diseases of the organs are treated using a rational, multi-tier approach. A patient is pretreated with growth factor proteins or gene therapy, followed by the administration of adult stem cells or other cell therapy. The patient can be a fetus treated in utero or removed from the womb. The progress of treatment is monitored by ultrasound, MRI, CAT scan, cardiac echo, EEG, EKG, EMG or blood tests, with growth factor treatment and / or stem cell administration adjusted according to the results of the monitoring or clinical status of the patient. Organ disease is also treated by a method that comprises administration of a therapeutically effective amount of a growth factor protein by oral inhalation or intranasal therapy. Diseases affecting organs such as the brain, spinal cord, pancreas, liver, kidney, muscle, heart and upper and lower gastrointestinal tracts are treated using the present method. A device for treatment is disclosed. CPK is utilized to assess the treatment of muscle disease.

The invention relates to methods and materials for enhancing muscle mass or for the treatment of muscle disease in a subject, comprising introducing a cell which has a lower than normal level of myostatin signalling, into the subject.

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits activity of a disease allele associated with muscle disease. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

An administration device comprising an array of needles, one or more fluid agents, and at least one hydrogel is described. The device can simultaneously deliver a plurality of fluid agents along respective axes into a tissue. The use of hydrogel leads to constrained delivery of the fluid agents. The constrained delivery of an agent is also achieved by depositing a drug implant into a tissue. The effect of an agent on the tissue can be evaluated thereafter. In addition, the invention is directed to treating muscle diseases by delivering a therapeutic agent in vivo, and the use of reporter tissues for candidate drug evaluation, detecting and characterizing resistance.

The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185erbB2 receptor. These compounds are found to cause increased differentiation and survival of cardiac, skeletal and smooth muscle.

The disclosure provides methods for treating neuromuscular disorders in mammals. The disclosed methods include administering therapeutically effective amounts of a GDF-8 inhibitor and a corticosteroid to a subject susceptible to, or having, a neuromuscular disorder, so as to maintain desirable levels of muscle function.

Duchenne muscular dystrophy (DMD) is a progressive muscle disease that is caused by severe defects in the dystrophin gene and results in the patient's death by the third decade. The present invention utilizes the Double Mutant mice (DM) as an appropriate human model for DMD as these mice are deficient for both dystrophin and utrophin (mdx / +, utrn − / −), die at 3 months of age and suffer from severe muscle weakness, pronounced growth retardation, kyphosis, weight loss, slack posture, and immobility. Expression from a transgene of novel human retinal dystrophin Dp260 was shown to prevent premature death and reduce the severe muscular dystrophy phenotype to a mild clinical myopathy. Electromyography, histology, radiography, magnetic resonance imaging, and behavior studies concluded that DM transgenic mice grew normally, had normal spinal curvature and mobility, and had reduced muscle pathology. EMG and histologic data from transgenic DM mice showed decreased abnormalities to levels typical of mild myopathy, while the DM mice exhibited severe abnormalities commonly seen in human dystrophinopathies. The transgenic DM mice also had measurable movement levels comparable to those of untreated mdx mice and controls.

The present invention relates to the use of proteins comprising at least one follistatin domain to modulate the level or activity of growth and differentiation factor-8 (GDF-8). More particularly, the invention relates to the use of proteins comprising at least one follistatin domain, excluding follistatin itself, for treating disorders that are related to modulation of the level or activity of GDF-8. The invention is useful for treating muscular diseases and disorders, particularly those in which an increase in muscle tissue would be therapeutically beneficial. The invention is also useful for treating diseases and disorders related to metabolism, adipose tissue, and bone degeneration.

A method of detecting neuromuscular pathology in an individual is disclosed comprising the steps of placing a detector on the skin surface of the individual substantially adjacent to a skeletal muscle; obtaining signals from the detector; processing the signals; and determining neuromuscular status in response to the signals. A system for detecting neuromuscular disease in an individual is disclosed, the system comprising at least one means for recording a first signal from a skeletal muscle; a filter in communication with the recording means to generate a second signal consisting substantially of spontaneous myoelectrical activity; and a processor in communication with the filter, wherein the first signal from the skeletal muscle is filtered so as to generate spontaneous myoelectrical signals, and further wherein the processor calculates the power spectral density of the filtered signals and determines the neuromuscular status in response to the power spectral density of the filtered signals.

Some aspects of the invention provide for a method of treating Alzheimer's Disease, Mild Cognitive Impairment, Frontotemperal Dementia, Amyotrophic Lateral Sclerosis and / or Multiple Sclerosis using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and / or suppress the rate of formation of reactive products and toxic compounds.

The invention aims at providing a muscle disease monitoring method based on multi-channel surface electromyography (sEMG). The method comprises the steps that preprocessing is conducted on multi-channel sEMG signals firstly, a first channel is selected as a reference, and differencing is conducted on the signals of other channels and the signal of the first channel; then distribution moments are extracted through a K-means clustering convolution kernel compensation (KMCKC) method, and a single waveform is extracted; finally, multiple features of the waveform are fused, and the muscle state is evaluated. Due to the fact that external interference has influence on all electrodes, by meas of differencing between the signal of the first channel and the sEMG signals of original multiple channels, the external interference is effectively reduced, subsequent detection results cannot be affected, and the accuracy of muscle detection is improved. By means of application of the multi-feature parameters, the instability of single-parameter monitoring is effectively avoided, and the monitoring robustness is promoted. By means of the muscle disease monitoring method based on the multi-channel surface electromyography (sEMG), the defects in the prior art are effectively overcome, and important application value is achieved.

The present invention provides novel methods for the modulation of autophagy and the treatment of autophagy-related diseases, including cancer, neurodegenerative diseases, liver diseases, muscle diseases and pancreatitis.

The invention relates to a muscle disease assessment method and system and an electronic device. The muscle disease assessment method includes the steps: a driving passive motion of a subject by external driving, and acquiring a motion angle of the subject; b acquiring dynamic change of detected skeletal muscle without the motion angle by the aid of an ultrasonic shear wave elasticity imaging technique, and extracting elasticity measurement data of the dynamic change; c extracting a corresponding relationship between elasticity modulus of the detected skeletal muscle and a joint angle from theelasticity measurement data, and taking the corresponding relationship between the elasticity modulus and the joint angle as characteristics to make a data set; d building a probabilistic neural network model, inputting the data set into a probabilistic neural network to perform training, and outputting a muscle disease of the subject and categories of the muscle disease by the probabilistic neural network. According to the method, by the aid of the artificial intelligence neural network, classification results are more reliable, generalization ability is better, and a new method is providedfor assessment of muscle diseases.

A Chinese medicine for treating the diseases of liver and tendon, such as cramp, spasm, stiff neck, fatty liver, alcoholic liver, and hepatocirrhosis, is proportionally prepared from white peony root, Chinese angelica root, liquorice root, honeysuckle flower and parched capejasmine fruit.

This invention provides nuclear hormone receptor binding compounds, compositions comprising the same and methods of uses thereof in treating a variety of diseases or conditions in a subject, including, inter-alia, prostate cancer and / or diseases or disorders of bone and muscle.

The invention belongs to the field of vector construction, and in particular relates to a recombinant bat adeno-associated virus vector and applications of the recombinant bat adeno-associated virus vector. Aiming at the problem of human antibody neutralizing existing in the AAV, the invention provides the recombinant bat adeno-associated virus vector, wherein an expression cassette of the recombinant vector comprises a REP gene of the human AAV2, a CAP gene of the bat AAV, and poly(A) signals in the sequence from the 5' terminal to the 3' terminal. Through expression regulation of a promoter,the recombinant vector can resist the neutralizing of the human-derived AAV antibody, meanwhile, the recombinant bat AAV vector has certain transduction capacity for the muscle tissue of mice. The recombinant bat adeno-associated virus vector provided by the invention can target to the muscle in vivo by carrying the target gene, and can resist the neutralizing of the human-derived AAV antibody, so that the recombinant bat adeno-associated virus vector has certain application prospect for the gene treatment of muscle diseases.

Acute and chronic diseases of the organs are treated using a rational, multi-tier approach. A patient is pretreated with growth factor proteins or gene therapy, followed by the administration of adult stem cells. The patient can be a fetus treated in utero or removed from the womb. The progress of treatment is continuously monitored by ultrasound, MRI, CAT scan, cardiac echo, EEG, EKG, EMG or blood tests, with growth factor treatment and / or stem cell administration adjusted according to the results of the monitoring or clinical status of the patient. Organ disease is also treated by a method that comprises administration of a therapeutically effective amount of a growth factor protein by oral inhalation or intranasal therapy. Diseases affecting organs such as the brain, spinal cord, pancreas, liver, kidney, muscle, and upper and lower gastrointestinal tracts are treated using the present method. A device for treatment is disclosed. CPK is utilized to assess the treatment of muscle disease.

The invention relates to application of Linc-RAM for treating muscle diseases. Specifically, the invention relates to application of Linc-RAM in preparation of medicines for treating muscle diseases, particularly muscle injury and rhabdomyosarcoma. Furthermore, the invention relates to application of the Linc-RAM in preparation of medicines for promoting differentiation of muscle stem cells, as well as reagents and medicines for promoting transition of fibroblast to myoblast.

The invention discloses application of miR-127 in preparation of medicines for treating muscle diseases. The invention provides application of any one of substances (1), (2) and (3) in preparation of medicines for treating muscle diseases: (1) miR-127; (2) a recombinant vector containing a coding gene of miR-127; and (3) a recombinant virus containing the coding gene of miR-127. The miR-127 can be used for preparing medicines for treating muscle diseases so as to effectively treat the muscle diseases.

The present invention relates to a composition for preventing or treating muscle diseases or improving muscular function, containing fucosterol, Sargassum fulvellum, a Sargassum fulvellum dried powder, a Sargassum fulvellum extract, Sargassum fusiforme, a Sargassum fusiforme dried powder or a Sargassum fusiforme extract. According to the present invention, fucosterol, Sargassum fulvellum, a Sargassum fulvellum dried powder, a Sargassum fulvellum extract, Sargassum fusiforme, a Sargassum fusiforme dried powder or a Sargassum fusiforme extract increases the protein expression of p-mTOR, which is a main gene involved in muscle protein synthesis, inhibits the mRNA expression of MuRF-1 and atrogin-1 involved in muscle protein degradation, and increases the mRNA expression of MyoD and myogenin involved in muscle differentiation, thereby having an effect of remarkably increasing muscular function. In addition, since the composition of the present invention is a natural product, the composition can be safely used without side effects, thereby being usable in medicine, food, cosmetic products, livestock feed, a feed additive and the like.

Animal models and methods wherein homoplasmic and heteroplasmic mtDNA mutation(s) are induced in an animal (e.g., a mouse) to cause or facilitate the development of a disorder (e.g., disease, malformation, defect, abnormality or other disorder). In at least some embodiments, the mtDNA mutation(s) will cause or facilitate the development of an age-related disorder, such as a cardiac disease, cardiomyopathy, muscle disease, cancer, abnormaly in tissues of high cellular turnover, heart dysfunction, graying of hair, alopecia, auditory function loss, cochlear degeneration, immune cell loss, anemia, male germ cell loss leading to lack of sperm and infertility, skeletal muscle mass loss (sarcopenia), neurodegeneration, increased presence of apoptotic markers, and loss of bone mass.

The present disclosure provides a method of treating muscle myopathy, including muscle dystrophies and cardiomyopathies, by administering stable, long-lasting vasoactive intestinal peptide therapeutic agents. These agents include one or more elastin-like peptides and can be administered at a low-dose.